Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs

R. Vrzal,

. 2016 ; 30 (3) : 248-52. [pub] 20160215

Language English Country England, Great Britain

Document type Journal Article

P-glycoprotein (P-gp) inhibition represents a promising therapeutic strategy for oncologic patients. The inhibition by naturally occurring anthocyans would bring certain benefits. Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy. However, due to the food supplementation, significant concentration can raise up in the intestine, where P-gp is abundantly expressed. As many drugs are orally taken, simultaneous administration might affect the concentration of these drugs in the blood. Here, we found that anthocyanidins (aglycons) but not anthocyanins (glycosides) can significantly inhibit P-gp up to 60% of positive control, verapamil. This inhibitory activity was observed for 500 μm concentrations of malvidin and pelargonidin. We conclude that these compounds may be the source of food-drug interactions either for orally taken drugs or for intravenously administered drugs eliminated via biliary excretion which are the substrates of P-gp.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024177
003      
CZ-PrNML
005      
20170906132631.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/fcp.12183 $2 doi
035    __
$a (PubMed)26821071
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vrzal, Radim $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
245    10
$a Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs / $c R. Vrzal,
520    9_
$a P-glycoprotein (P-gp) inhibition represents a promising therapeutic strategy for oncologic patients. The inhibition by naturally occurring anthocyans would bring certain benefits. Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy. However, due to the food supplementation, significant concentration can raise up in the intestine, where P-gp is abundantly expressed. As many drugs are orally taken, simultaneous administration might affect the concentration of these drugs in the blood. Here, we found that anthocyanidins (aglycons) but not anthocyanins (glycosides) can significantly inhibit P-gp up to 60% of positive control, verapamil. This inhibitory activity was observed for 500 μm concentrations of malvidin and pelargonidin. We conclude that these compounds may be the source of food-drug interactions either for orally taken drugs or for intravenously administered drugs eliminated via biliary excretion which are the substrates of P-gp.
650    _2
$a aplikace orální $7 D000284
650    _2
$a zvířata $7 D000818
650    _2
$a anthokyaniny $x aplikace a dávkování $x metabolismus $7 D000872
650    12
$a potravní doplňky $7 D019587
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a fluoresceiny $x aplikace a dávkování $x metabolismus $7 D005452
650    12
$a interakce mezi potravou a léky $x fyziologie $7 D018565
650    _2
$a lidé $7 D006801
650    _2
$a P-glykoprotein $x antagonisté a inhibitory $x metabolismus $7 D020168
650    _2
$a prasata $7 D013552
650    _2
$a verapamil $x aplikace a dávkování $x metabolismus $7 D014700
655    _2
$a časopisecké články $7 D016428
773    0_
$w MED00001866 $t Fundamental & clinical pharmacology $x 1472-8206 $g Roč. 30, č. 3 (2016), s. 248-52
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26821071 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906133229 $b ABA008
999    __
$a ok $b bmc $g 1239858 $s 985090
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 3 $d 248-52 $e 20160215 $i 1472-8206 $m Fundamental & clinical pharmacology $n Fundam Clin Pharmacol $x MED00001866
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...